BackgroundRecent open-label trials show that psychedelics, such as ayahuasca, hold
promise as fast-onset antidepressants in treatment-resistant depression.MethodsTo test the …

… Riba J, Barbanoj MJ. Bringing ayahuasca to the clinical … Riba J, Barbanoj MJ. Bringing
ayahuasca to the clinical … Riba J, Barbanoj MJ. Bringing ayahuasca to the clinical research …

Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine,
a 5-HT 2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group …

Schizophrenia is a heterogeneous psychiatric disorder that is poorly treated with current
therapies. In this brief review, we provide an update regarding the use of animal models to study …

… Funding/Support: This work was supported by grant 2007/03685-3 from Fundação de Amparo
à Pesquisa do Estado de São Paulo (Dr Maia-de-Oliveira). Drs Hallak, Zuardi, and Crippa …

Serotonergic psychedelics are emerging as potential antidepressant therapeutic tools, as
suggested in a recent randomized controlled trial with ayahuasca for treatment-resistant …

Background: Ayahuasca is a traditional Amazon brew and its potential antidepressant properties
have recently been explored in scientific settings. We conducted a double-blind placebo…

Major depression is a highly prevalent mood disorder, affecting about 350 million people, and
around 30% of the patients are resistant to currently available antidepressant medications. …

Rationale The devastating nature of schizophrenia and treatment limitations have triggered
a search for early detection methods to enable interventions to be implemented as soon as …

The comprehension of the pathophysiology of the major depressive disorder (MDD) is
essential to the strengthening of precision psychiatry. In order to determine the relationship …